Roche just put a real number on the obesity drug it has been quietly building. At the American Diabetes Association 2026 Scientific Sessions (June 5-8, New Orleans), the company presented late-breaking Phase 2 data showing its dual GLP-1/GIP agonist enicepatide (CT-388) drove 22.5% placebo-adjusted weight loss at 48 weeks — and the curve had not flattened.
That puts a third pharma giant squarely in the same incretin race as the tirzepatide and retatrutide franchises. Here is what the data actually says, and what it means if you are buying peptides today.
The News: What Roche Reported
The data come from CT388-103 (NCT06525935), a Phase 2 dose-ranging trial of once-weekly subcutaneous enicepatide in adults with overweight or obesity. The top dose was titrated up to 24 mg once weekly over a 48-week treatment period.
At 48 weeks, the 24 mg arm delivered:
| Metric (24 mg, 48 wk) | Result |
|---|---|
| Placebo-adjusted weight loss (efficacy estimand) | 22.5% (p < 0.001) |
| Placebo-adjusted weight loss (treatment-regimen estimand) | 18.3% (p < 0.001) |
| Lost ≥5% body weight | 95.7% |
| Lost ≥10% body weight | 87% |
| Lost ≥20% body weight | 47.8% |
| Lost ≥30% body weight | 26.1% |
| Resolved obesity (BMI < 30) | 54% (vs 13% placebo) |
| Prediabetics returning to normal glucose | 73% (vs 7.5% placebo) |
Two details stood out to analysts. First, weight loss had not plateaued by week 48 — the trajectory suggests more was on the table with longer treatment. Second, the safety profile held up: gastrointestinal adverse events were mostly mild-to-moderate, and discontinuation due to adverse events was 5.9% in the enicepatide arms versus 1.3% on placebo — low for an incretin drug at this efficacy level (Roche, ADA 2026; Roche press release, January 27, 2026).
The Mechanism Twist: Biased Signaling
Enicepatide is a dual GLP-1/GIP agonist — the same receptor pair as tirzepatide. What's different is how it engages those receptors. It was engineered for a biased-signaling profile that minimizes beta-arrestin recruitment at both receptors. Beta-arrestin drives receptor internalization and desensitization, so reducing it is meant to keep the receptors responsive for longer. The "no plateau at 48 weeks" finding is consistent with that design thesis, though it will take Phase 3 to confirm it translates into durable real-world results.
That mechanistic angle is why enicepatide is worth paying attention to even though tirzepatide already owns the GLP-1/GIP space. It is not a me-too molecule; it is a bet that signaling quality, not just receptor targets, determines how far incretin weight loss can go.
What This Means for You
Here is the honest part: enicepatide is years away. Roche advanced it into Phase 3 (the ENITH program) in early 2026, with additional Phase 2 readouts in type 2 diabetes and a petrelintide combination expected before year-end. A realistic FDA approval window is 2028-2029 at the earliest, and only if Phase 3 holds. No research-peptide vendor stocks it, and none will until well after approval.
So the practical takeaway is not "wait for enicepatide." It is that the dual- and triple-incretin mechanism it validates is already buyable today in the form of tirzepatide and retatrutide. If the appeal of CT-388 is the GLP-1/GIP combination, tirzepatide is that combination, available now. If the appeal is the highest achievable weight loss, retatrutide's triple-agonist Phase 3 (28.3% in TRIUMPH-1) is the current ceiling.
For the available options, compare live vendor pricing here:
- Best retatrutide vendors — triple agonist, highest Phase 3 weight loss to date
- Best tirzepatide vendors — the dual GLP-1/GIP option enicepatide is chasing
- Best semaglutide vendors — the original GLP-1 benchmark
- All vendor coupons and deals — current discounts across recommended vendors
